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Abstract
Cell lineages of the early human gonad commit to one of the two mutually antagonistic organogenetic fates, the testis or the
ovary. Some individuals with a 46,XX karyotype develop testes or ovotestes (testicular or ovotesticular disorder of sex
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development; TDSD/OTDSD), due to the presence of the testis-determining gene, SRY. Other rare complex syndromic forms
of TDSD/OTDSD are associated with mutations in pro-ovarian genes that repress testis development (e.g. WNT4); however,
the genetic cause of the more common non-syndromic forms is unknown. Steroidogenic factor-1 (known as NR5A1) is a key
regulator of reproductive development and function. Loss-of-function changes in NR5A1 in 46,XY individuals are associated
with a spectrum of phenotypes in humans ranging from a lack of testis formation to male infertility. Mutations in NR5A1 in
46,XX women are associated with primary ovarian insufficiency, which includes a lack of ovary formation, primary and sec-
ondary amenorrhoea as well as early menopause. Here, we show that a specific recurrent heterozygous missense mutation
(p.Arg92Trp) in the accessory DNA-binding region of NR5A1 is associated with variable degree of testis development in 46,XX
children and adults from four unrelated families. Remarkably, in one family a sibling raised as a girl and carrying this NR5A1
mutation was found to have a 46,XY karyotype with partial testicular dysgenesis. These unique findings highlight how a spe-
cific variant in a developmental transcription factor can switch organ fate from the ovary to testis in mammals and repre-
sents the first missense mutation causing isolated, non-syndromic 46,XX testicular/ovotesticular DSD in humans.
Introduction
Disorders of (or differences in) sex development (DSD) are de-
fined as congenital conditions in which the development of
chromosomal, gonadal or anatomical sex is atypical (1,2).
Classic forms of DSD affect approximately one in every 2000 to
4000 people and may present in many ways, such as a baby
with atypical genitalia where it cannot immediately be said
whether the newborn is a boy or girl, or a teenage girl with pri-
mary amenorrhoea. Related conditions, such as hypospadias,
are more prevalent, affecting up to one in 300 boys.
DSDs encompass a wide range of different aetiologies (1–3).
Sex chromosome mosaicism (45,X/46,XY) and 46,XY DSD (go-
nadal dysgenesis, disorders of androgen synthesis and action)
are relatively common causes, whereas most individuals with
46,XX forms of DSD have congenital adrenal hyperplasia (CAH;
MIM: 202010). Importantly, a subset of individuals with a 46,XX
karyotype has ovotestes or testes rather than an adrenal condi-
tion. These forms of ovotesticular DSD (OTDSD) and testicular
DSD (TDSD) were historically known as “true hermaphroditism”
and “XX males”, respectively, and need different approaches to
counselling and management compared to CAH (2,3).
Our molecular understanding of the causes of OTDSD/TDSD is
incomplete. Some individuals with OTDSD/TDSD have upregula-
tion of genes involved in testis determination (e.g. SRY MIM:
400045, SOX9 MIM: 278850, SOX3 MIM: 300833), whereas others
have reduced function of genes expressed in the developing ovary
that repress testis development (e.g., RSPO1 MIM: 610644, WNT4
MIM: 611812; 4–9). To date, coding mutations in single genes caus-
ing non-syndromic OTDSD/TDSD have not been described.
NR5A1, also known as steroidogenic factor-1 (SF-1) is a nu-
clear receptor transcription factor with key roles in reproductive
development and function (10). Loss-of-function changes in
NR5A1 are associated with a wide spectrum of conditions includ-
ing gonadal (testicular) dysgenesis (MIM: 612965), hypospadias,
and male factor infertility (MIM: 613957) in 46,XY individuals, as
well as primary ovarian insufficiency (POI, MIM: 612964) in 46,XX
women (11–15). Here, we show that a recurrent heterozygous
point mutation in NR5A1 is associated with OTDSD/TDSD devel-
opment in 46,XX individuals in four families of different ancestry.
Results
Clinical phenotypes
Family 1, of European-American ancestry, have two 46,XX chil-
dren with ovotestes (Figure 1A; Table 1) . The first child (1.1) pre-
sented with atypical (“ambiguous”) genitalia at birth. Gonads
were palpable in the right inguinal region and higher in the left
labioscrotal fold. The karyotype was 46,XX (SRY-negative) and
17-hydroxyprogestone was low, excluding CAH. Gonadal biop-
sies showed dysgenetic testicular tissue. Vaginoscopy revealed
a rudimentary vagina and uterine cervix. Following discussions
with the parents, the female sex assignment was considered
appropriate. Gonadal histology showed a left dysgenetic testis
and right ovotestis, with a 46,XX karyotype in this tissue. A diag-
nosis of OTDSD was made. A second child (1.2) presented with
similar genitalia at birth (Figure 1A; Table 1). Investigations re-
vealed a 46,XX karyotype, intra-abdominal gonads and a uterus.
Gonadal histology showed bilateral ovotestes, suggesting a di-
agnosis of familial OTDSD. The mother had no known androge-
nization but had menopause at the age of 40 years.
Family 2, of Latino/Hispanic ancestry, have a boy (2.1) who
was referred at seven months of age because of a small penis
that was partly buried in suprapubic fat (stretched length 2.8cm,
typical range 4.3cmþ/ 0.8) (Figure 1A; Table 1). Both gonads
were palpable at the time. At 9 months of age, chromosome
analysis and ultrasound were ordered as the gonads were no
longer palpable. A 46,XX karyotype (SRY-negative) was observed
and two structures in the inguinal regions (1.3 0.5 0.7cm;
0.9 0.5 0.7cm) that had morphological and Doppler appear-
ances of testes. Anti-Mu¨llerian Hormone (AMH, MIS) (478 pmol/l
[342–594]) and inhibin B (85 pg/ml [40–630]) concentrations were
within normal ranges for a child with testes and a good
testosterone response was seen following three days stimula-
tion with human chorio-gonadotropin (basal<0.1 nmol/l, peak
15.1 nmol/l). No testicular biopsy was done. The diagnosis of
46,XX TDSD was made.
Family 3, of African and African-American ancestry, have a
son (3.1) who presented with small testes and low testosterone
at 16 years of age (Figure 1A; Table 1). He was on testosterone
supplementation inconsistently through his late teens and 20s.
At 30 years of age, he was found to have bilateral atrophic testes
(less than 5cc) and small phallus (5–6 cm stretched length).
Genetic evaluation showed a 46,XX karyotype (SRY-negative)
with a normal microarray. Endocrine evaluation showed pri-
mary testicular failure, based on very low testosterone (34 ng/dL
[300–1080]), raised gonadotrophins (FSH (25 mIU/mL [1.3–11.4])
and LH (15 mIU/ml [1.2–7.8])), and low AMH (0.657 pmol/l [15–
219.2]) and inhibin B (<10 pg/ml [40–450]). Adrenal function and
sex-hormone binding globulin levels were normal. Testosterone
levels remained low following a 4-day hCG stimulation test (tes-
tosterone 46 ng/dL, androstenedione 0.272 ng/ml [0.33–1.34], and
dihydrotestosterone 55 pg/ml [112–955]). Semen analysis
showed azoospermia. The diagnosis of 46,XX TDSD was made.
Family 4, of South Asian ancestry, have an older girl (4.1)
who was seen in six years of age because of labial fusion and
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mild clitoral enlargement. The karyotype was 46,XY (SRY-posi-
tive) (Figure 1A; Table 1). Gonads were palpable in the inguinal
region, which were dysgenetic testes on histology. No uterus
was found and a diagnosis of partial gonadal (testicular) dysgene-
sis was made. A younger brother (4.2) had severe penoscrotal hy-
pospadias but palpable gonads in the scrotum. Biopsy of the right
testis showed dysgenetic testicular tissue (Figure 1B).
Surprisingly, the karyotype was 46,XX (SRY-negative), suggesting
a diagnosis of 46,XX TDSD (Figure S1). The mother has no re-
ported androgenisation but has had very irregular periods all her
life. This family therefore has a 46,XY girl with partial gonadal
dysgenesis and a 46,XX boy with TDSD who are siblings.
NR5A1 p.Arg92Trp mutation associated with 46,XY DSD
and 46,XX OTDSD/TDSD
In families 1, 2 and 3, whole exome (1 & 2) and whole genome
sequencing (3), respectively, revealed a heterozygous NR5A1
mutation p.Arg92Trp (p.R92W, c.274C>T) as the best candidate
for the phenotype (Figure 1A and C; Table 1). In Family 4 direct
sequencing of NR5A1 revealed the same heterozygous mutation
in the 46,XX TDSD boy and in his older sister who had 46,XY
partial gonadal dysgenesis. This p.Arg92Trp change was in-
herited from the mother in families 1 and 4, but was de novo in
family 2. In family 3, the mutation was not present in the father.
The child’s mother was deceased and a DNA sample was not
available for sequencing. However, haplotype reconstruction by
direct comparison of the genotypes in the affected child and fa-
ther indicated a strong likelihood of the variant being de novo on
the paternal allele based on direct phasing in the patient and
evaluation of the rare paternal haplotype shared by both the
proband and his father (Supplementay Material, Results and
Fig. S2). The p.Arg92Trp variant was not identified in NR5A1 in
more than 800 known fertile individuals and was absent
from>70,000 individuals present in public databases. Moreover,
our families were unrelated and came from geographically
A C
B
E
D
Figure 1. Identification and modelling of the NR5A1 p.Arg92Trp variant. (A) Shows the pedigrees of the four families with the affected members shaded. Squares denote
individuals brought up as boys and circles denote individuals brought up as girls, with respective karyotypes shown below. (B) Shows testicular histology from individ-
ual 4.2 with 46,XX testicular DSD. (C) Shows sequence chromatograms of the wild-type and p.Arg92Trp NR5A1. (D) Shows the sequence alignment of the A-box motif in
selected vertebrae, together with a schematic representation of the NR5A1 protein. (E) Shows the model of wild-type NR5A1 and p.Arg92Trp DNA-binding domain in
complex with DNA. The RGGR motif of the A-box interacts with the minor groove of DNA. The basic arginine residue (Arg, R) in wild-type NR5A1 (left panel) is replaced
by a neutral tryptophan residue (Trp, W) with a bulky indole side chain (right panel).
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distinct regions, excluding a founder effect for a rare variant. All
46,XX children were SRY-negative and exome or genome se-
quencing in family 1, subject 2.1 and subject 3.1 did not show
any other likely pathogenic causes. Furthermore in family 1, a
hidden Y chromosome mosacism was excluded by both FISH
analysis and the absence of SRY amplification by PCR using
DNA from gonadal tissue.
In silico analysis predicts a disruptive effect of
p.Arg92Trp on DNA binding
The p.Arg92Trp mutation affects a highly conserved amino acid
in the RGGR motif of the “A-box” of NR5A1 (Figure 1D). This mo-
tif interacts with the minor groove of DNA to stabilize the mo-
nomeric binding by NR5A1 (Figure 1E). The mutation replaces a
polar arginine with a bulky tryptophan and likely alters hydro-
gen bonding between NR5A1 and DNA in this region (Figure1E)
(see also Supplementary Material, Figures S3 and S4).
NR5A1 is expressed in somatic cells of the early
embryonic ovary
In order to assess whether NR5A1 is expressed in the early hu-
man ovary, studies were performed using foetal tissue between
6–10 wpc. In contrast to the mouse, where Nr5a1 is expressed
specifically in the somatic cells of the early testis and only trace
expression is observed in the early ovary (16,17), we found that
the expression of human NR5A1 was similar in the ovary and
testis and significantly greater than in control tissue (data not
shown). NR5A1 protein localized specifically to the nuclei of so-
matic cells in the ovary (Figure 2A). These data show that
NR5A1 is expressed in ovarian somatic cells that can regulate
cell fate at an early stage.
P.Arg92Trp alters the biological activity of the protein
We hypothesized that the p.Arg92Trp mutation could be associ-
ated either with inappropriate activation of testis-specific path-
ways in the ovary, or with disruption of the pathways that
oppose testis development and maintain ovarian integrity. In
general, the p.Arg92Trp NR5A1 mutant showed loss of binding
to a consensus NR5A1 response element and reduced activation
of several minimal promoters (Amh, Cyp11a1) and enhancers
(Sox9 Tesco) involved in testis development (Figures 2B and 2C,
and Supplementary Material, Figure S5) consistent with 46,XY
partial gonadal dysgenesis seen in the girl (4.1). Furthermore,
the p.Arg92Trp NR5A1 mutant was unable to upregulate endog-
enous Sox9 expression in mouse XX Sf1-GFPþ gonadal support-
ing cells compared to the WT NR5A1 protein (Supplementary
Material, Figure S6). We recently described a homozygous p.
Arg92Gln mutation in a girl with adrenal insufficiency and no
ovotestis (18). We assayed the ability of these two different mu-
tations to influence the pro-ovary canonical WNT/RSPO1 signal-
ling pathway using the TOP-Flash reporter system. b-catenin
has been shown to interact functionally with NR5A1 to activate
target genes synergistically, including Nr0b1 (Dax-1). In contrast
to p.Arg92Gln, the p.Arg92Trp NR5A1 mutant showed selective
loss of synergy with b-catenin (Figure 2D). Therefore, the pheno-
type in the 46,XX children with the p.Arg92Trp variant may be
due to altered expression of ovarian factors that oppose testis
development.
Discussion
When a child presents with potential differences in sex devel-
opment, making a specific diagnosis can have important impli-
cations for management and for supporting the family and
young person appropriately (2,3,19). Most children with a
46,XX karyotype and atypical genitalia will have a form of CAH,
usually due to 21-hydroxylase deficiency, and will require
urgent investigation and adrenal steroid replacement. However,
less common conditions such as ovotesticular DSD should
also be considered in a baby with atypical genitalia, or testicular
DSD in a boy with a 46,XX karyotype. Men with 46,XX testicular
DSD typically present with small testes, testosterone insuffi-
ciency and infertility. Such individuals are often diagnosed
through infertility clinics as several Y chromosomal genes are
required to support spermatogenesis and two X chromosomes
is deleterious for germ cell development in the XX testis.
Experienced genetic counselling and support are needed to help
the young person understand their condition and how it might
Table 1. Overview of the genetic and phenotypic features of children and adults with ovotesticular and testicular DSD
Individual 1.1 1.2 2.1 3.1 4.1 4.2
Karyotype 46,XX 46,XX 46,XX 46,XX 46,XY 46,XX
SRY – – – – þ –
NR5A1 p.Arg92Trp p.Arg92Trp p.Arg92Trp p.Arg92Trp p.Arg92Trp p.Arg92Trp
Inheritance Maternal Maternal de novo ade novo Maternal Maternal
Sex assignment Female Female Male Male Female Male
Presentation “Ambiguous”
genitalia
“Ambiguous”
genitalia
Small penis;
retractile testes
Small testes;
low testosterone
Mild clitoromegaly;
labial fusion
Penoscrotal
hypospadias
Gonad position L: inguinoscrotal;
R: inguinal
Intra-abdominal Scrotal (retractile) Scrotal Inguinal Scrotal
Gonad
histology
L: dysgenetic testis;
R: ovotestis
b Bilateral
ovotestes
c N/A N/A Dysgenetic testes Dysgenetic testes
Uterus R: hemiuterus Uterus No uterus No uterus No uterus No uterus
DIagnosis 46,XX ovotesticular
DSD
46,XX ovotesticular
DSD
46,XX testicular
DSD
46,XX testicular
DSD
46,XY partial
gonadal dysgenesis
46,XX testicular
DSD
ainferred from paternal haplotype (see Supplemental data and Fig. S2);
bhistology reported primitive ova structures;
cultrasound reported two testes with normal colour Doppler blood flow/spectral waveforms and biochemistry was consistent with the presence of testicular tissue.
N/A. not available.
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affect their future. Given the increasingly recognized role of
NR5A1 in many reproductive phenotypes a detailed family his-
tory is needed as other family members might be affected and
could benefit from endocrine evaluation and appropriate
counselling.
In humans, the embryonic gonad remains “bipotential” un-
til around 6 wpc. In the developing testis, expression of the
testis-determining gene SRY leads to upregulation of SOX9
and subsequent stimulation of testis-specific pathways
(Figure 2E; 20). Although poorly understood, it is emerging
that many ovary-specific genes and pathways exist (21). Some of
these signalling pathways, such as R-spondin-1 and WNT4, mod-
ulate their effects via b-catenin to “oppose” testis development
by attenuating factors such as SOX9 (9,22,23).
NR5A1 clearly plays an important role in supporting testis
development at multiple stages and loss of NR5A1 is associated
with a wide range of testicular phenotypes. The relative pheno-
types in Families 2 and 3 point to a differential ability of the
NR5A1 mutant in sustaining in Sertoli and Leydig cell function
early in human embryological development vs. later in
A
C
E
D
B
Figure 2. Expression, functional analyses and model of NR5A1 p.Arg92Trp acting as a cell fate switch. (A) Shows expression of NR5A1 in somatic cells of the developing
ovary with germ cells shown by POU5F1 (OCT4) (9 wpc) (upper panel). Negative controls without primary antibody are shown below. Nuclei are stained blue with DAPI.
Scale bar denotes 50 mm. (B) Demonstrates that the mutant NR5A1 p.Arg92Trp lacks the ability to bind to a known consensus target sequence. (C) Shows a reduced abil-
ity of the NR5A1 mutant protein to activate reporter activity using the Tesco enhancer element as a target in HEK 293-T cells. (D) HEK 293-T cells were transfected with
multimerized TCF/LEF1 binding sites containing the luciferase reporter construct (TOPFlash). Co-transfection with the vectors pCSb-catenin with pCMX-NR5A1 WT,
pCMX-NR5A1p.Arg92Gln or pCMX-NR5A1p.Arg92Trp showed that in contrast to both the NR5A1 WT and NR5A1 p.Arg92Gln proteins the NR5A1 p.Arg92Trp showed a
reduced ability to synergise with b-catenin to up-regulate reporter gene activity. Similar results were obtained using KGN cells (data not shown). All results are ex-
pressed as meanþ/- S.D. of at least three experiments. (E) shows a potential model based on the in vitro data. Left: in a 46,XY individual NR5A1 synergises with SRY to
upregulate SOX9 expression leading to testis formation. Left centre: in 46,XX individuals, NR5A1 syngerises with b-catenin to upregulate the expression of anti-testis
genes (e.g. DAX-1/NR0B1). Right centre: In the 46,XY DSD case (4.1) the p.Arg92Trp mutant shows a reduced ability to up-regulate SOX9 gene expression leading to a
lack of testis formation. Right: In a 46,XX child with TDSD/OTDSD, the same mutant shows reduced ability to synergise with b-catenin to up-regulate the expression of
anti-testis genes. As a consequence of this lack of repression, the expression of pro-testis genes (e.g. SOX9) leads to testis formation.
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postnatal life. Both subjects had evidence of testicular descent
and absent Mu¨llerian structures supporting functional Sertoli
and Leydig cell activity. However, the subject in family 3 had no
endocrinological evidence of such function in adult life (no in-
hibin B, AMH, and negative HCG stimulation) supporting the
adult requirement for NR5A1 for maintaining Sertoli and Leydig
cell function. The p.Arg92Trp mutant NR5A1 also likely disrupts
pro-testis pathways to some extent given the results of func-
tional studies as well as the partial testicular dysgenesis seen in
the 46,XY girl in Family 4.
In contrast to the effects on testis development pathways,
we suggest that the p.Arg92Trp NR5A1 variant switches organ
fate from ovary to testis through disruption of ovary-specific
pathways that would normally oppose testis development,
rather than by activating testis pathways directly (Figure 2E).
Indeed, our data show that, in contrast to the mouse model,
NR5A1 is expressed in the somatic cells of the developing hu-
man ovary, and the p.Arg92Trp NR5A1 mutant shows a reduced
ability to interact with b-catenin to synergistically activate re-
porter gene activity (16,17,24). Of note, a similar effect was not
seen with the p.Arg92Gln mutant (Figure 2D), an NR5A1 variant
which has been reported recently in a 46,XX girl without ovo-
testes (18). The expression of Nr5a1 in the mouse embryonic go-
nad is sexually dimorphic. In contrast to its continuous
expression in the mouse embryonic testis, Nr5a1 transcripts are
absent during the period of ovarian formation between E13.5-
E16.5 (25). The absence of expression during ovarian formation
suggests that a mouse model of the p.Arg92Trp mutant may not
generate the same phenotype in XX mice and furthermore there
is no guarantee that the p.Arg92Trp substitution will be patho-
genic in the context of the mouse polypeptide.
Phenotype expression can be variable with NR5A1, as is of-
ten the case for developmental disorders. Children (46,XX) har-
bouring the p.Arg92Trp mutation had a phenotypic spectrum
ranging from atypical (“ambiguous”) genitalia and a uterus to a
phenotypic male with testes. Moreover, the mothers in families
1 and 4 transmitted the variant but had mild potential features.
Possibly a second genetic variant could have accounted for vari-
able penetrance, but no obvious factors were identified by
exome sequencing. In addition, identification of this specific
p.Arg92Trp change in multiple members of unrelated families
of diverse ancestry suggests that it is the primary genetic driver
of the condition. Sex development is exquisitely sensitive to
dose-dependent effects. If a critical threshold of testis-
determining factor function (e.g., SOX9) is reached then the tes-
tis development pathway will result, and a testis (or ovotestis)
will form. We suspect that critical thresholds have been
reached in these children, whereas these have not in the
mothers. Indeed, familial cases would by definition only be iden-
tified if the mother had mild features and maintained fertility
(26–28).
This report highlights the complexity of human sex develop-
ment, reveals subtle but potentially important differences with
the mouse system and it reveals a novel genetic cause of non-
syndromic testis development in 46,XX individuals.
Remarkably, a single amino acid change in a key transcription
factor can function as a bidirectional switch the choice of devel-
opmental fate of tissues in early embryonic life.
Materials and Methods
Complete methods are described in detail in Supplementary
Material, Materials and Methods.
Ethics committee approval and written informed consent was
obtained (Supplementary Material, Methods). Exome sequencing
and direct sequencing of NR5A1 was performed as described in
the Supplemental Methods. Control data for NR5A1 was obtained
from direct sequencing of healthy fertile controls and public vari-
ant databases (Supplementary Material, Methods). Models of
wild-type, p.Arg92Gln NR5A1 and p.Arg92Trp NR5A1 (hSF-1,
Uniprot Q13285) in complex with DNA were generated with
MODELLER software (29) and the crystal structure of mouse
Nr5a1 bound to the inhibin a-subunit promoter (PDBid 2FF0) as a
template (Supplementary Material, Methods). Human embryonic
and fetal tissues were obtained from the Human Developmental
Biology Resource (www.hdbr.org) following ethical approval and
with informed consent (see Supplementary Material, Methods).
Binding of wild-type and mutant NR5A1 to a consensus NR5A1
DNA binding site (CCAAGGTCA) was assessed using electromo-
bility shift assays. Transient gene activation studies of NR5A1
were performed for wild-type and mutant cDNA using a range of
different putative NR5A1 targets (Amh, Cyp11a1, Tesco) in differ-
ent cell lines (HEK, KGN, NT2D1, mouse embryonic stem cells;
23). Synergistic activation of the TOP-Flash reporter system by
NR5A1 and b-catenin binding was studied as reported previously
(24 and see Supplementary Methods).
Supplementary Material
Supplementary Material is available at HMG Online.
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